Overview

Ethyl-EPA Treatment of Prodromal Patients

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Yale University
Treatments:
Eicosapentaenoic acid ethyl ester